Saturday 17 October 2026
Export CELU’s income statement to Excel — free account
Celularity, Inc.
CELU Healthcare Biotechnology
Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024. In the quarter to March 2026, revenue fell 66.3%, EPS grew 103.6%, free cash flow grew 148.4% and total debt fell 4.73%, each against the same quarter a year earlier.
1.25
0.08
−6.02%
Follow CELU
Celularity, Inc. (CELU) P/E ratio
Celularity, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 15.6× (February 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 11.5× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| 19 more quarters | Free account |
Against its own ten years
Low 0.0×
High 15.6×
Ten-year median
0.0×
Current reading's percentile
82
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ANVS Annovis Bio, Inc. compare | n/m |
| VERU Veru Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| SGMOQ Sangamo Therapeutics, Inc. compare | n/m |
| CELU Celularity, Inc. | n/m |
| GRCE Grace Therapeutics, Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| SER Serina Therapeutics, Inc. compare | n/m |
| TIL Instil Bio, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)